Abbott Laboratories

Strategic intent

Abbott Laboratories is a global healthcare leader that develops, manufactures, and sells medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products.

Key market signals

• 2026-10: Abbott announced plans to separate its global Nutrition business (generating ~$8.5 billion in annual sales) into an independent, publicly traded company by the end of 2027, to be led by Daniel Salvadori.
• 2026-08: Abbott resolved the Gill lawsuit and approximately 2,000 other NEC preterm infant formula claims for an aggregate settlement of $670 million.
• 2026-09: Abbott agreed to pay $384.99 million to settle federal and state False Claims Act allegations regarding unsanitary manufacturing conditions at its infant formula plants.
• 2026-03: Abbott completed the acquisition of Exact Sciences, integrating its Cologuard screening test and oncology assets into Abbott's new Cancer Diagnostics business.
• 2026-08: Abbott received FDA approval for Libre Duo, the world's first dual glucose-ketone biowearable sensor, expanding its continuous glucose monitoring portfolio.

Financial health

• In Q3 2026, Abbott reported net sales of $13.013 billion (up 14.5% reported, 7.0% comparable year-over-year) and GAAP diluted EPS of $0.53 (adjusted diluted EPS of $1.42) (https://www.abbottinvestor.com).
• For the first nine months of 2026, Abbott reported net sales of $36.770 billion and net income of $2.925 billion (https://www.marketscreener.com).
• Abbott trimmed its full-year 2026 comparable sales growth guidance to approximately 6.0% and tightened its adjusted diluted EPS guidance to $5.50 to $5.55 (https://www.zacks.com).

Impact & compliance

Legal & risks

In September 2026, Abbott Laboratories agreed to pay $384,999,040 to settle DOJ allegations of manufacturing infant formula in unsanitary conditions. In August 2026, Abbott Laboratories agreed to pay $670 million to settle claims that its Similac cow's milk-based infant formula contributed […]

Forensic audit — 3 findings

• ⚠ In April 2026, Abbott Laboratories and AbbVie filed motions to dismiss nearly 140 lawsuits in Cook County, Illinois, all...
• ⚠ In August 2026, a federal judge in California rejected much of Abbott Laboratories' motion for summary judgment in a law...
• ⚠ In June 2026, a federal whistleblower complaint was filed by former sales representative Kris Ghosh, alleging that Abbot...

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.